GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

There are also a host of other multiple myeloma drugs in the pharma pipeline – there are high hopes for drugs such as GSK’s belantamab mafodotin, an antibody-drug conjugate that produced ...

A: Avastin; Ag: Antigen; mAb: Monoclonal antibody; MM: Multiple myeloma ... conjugates are a novel strategy aiming to minimize side effects of chemotherapy and specifically deliver cytotoxic drugs ...

The theory behind antibody drug conjugates (ADCs ... tumours like in Hodgkin’s and Non-Hodgkin’s lymphoma or multiple myeloma Given these three dimensions, we conclude that an increased ...

LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...